Search results
Results from the WOW.Com Content Network
IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. [2] [3] [4] IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. [5] In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green ...
Sorrell v. IMS Health Inc., 564 U.S. 552 (2011), [1] is a United States Supreme Court case in which the Court held that a Vermont statute that restricted the sale, disclosure, and use of records that revealed the prescribing practices of individual doctors violated the First Amendment.
Throughout its history, the legacy IMS Health's business of collecting anonymized pharmaceutical sales data came under scrutiny from both the media and the legal system. [32] IMS Health v. Ayotte was a free speech case involving IMS Health. [33] [34] [35] Sorrell v.
The bust was the “largest ever criminal enforcement action targeting distributors of pharmaceutical opioids and commonly abused prescription drugs with estimated street value of $1.3 billion ...
Global pharmaceutical sales are expected to grow by 5% to 7% in 2011 to around $880 billion, compared with a rise of 4% to 5% this year, thanks to robust growth in emerging markets, especially ...
Ista Pharmaceutical: $14.6 $11.3 $8.3 $2.6 bromfenac: Xibrom Ocular inflammation Ista Pharmaceutical: $63 $42.1 $20.2 $5.3 hyaluronidase: Vitrase Spreading agent Ista Pharmaceutica: $5.2 $5.2 $4.2 $2.5 rivaroxaban: Xarelto Deep vein thrombosis Johnson & Johnson [39] $1,868 $1,522 $864 $239 $25
2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban: anticoagulant: Eliquis 9872 7395 4 lenalidomide: multiple myeloma: Revlimid 9685 8187 5 nivolumab: oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 ...
From January 2008 to December 2012, if you bought shares in companies when James D. Robinson III joined the board, and sold them when he left, you would have a 18.0 percent return on your investment, compared to a -2.8 percent return from the S&P 500.